Post-authorization Safety Study: Ponesimod Pregnancy Outcomes Program Utilizing Enhanced Pharmacovigilance Monitoring (POEM) First published 05/12/2022 Last updated 12/12/2024 EU PAS number:EUPAS50031 Study Ongoing